Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Avvio Medical
Study ID
NCT06942949
Status
Recruiting

Conditions

  • Kidney Calculi; Ureteral Calculi

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ELS (Enhanced Lithotripsy System) — DEVICE
    ELS (Enhanced Lithotripsy System) utilizes low pressure ultrasound to actuate proprietary microbubbles administered into the urine to pit and fragment urinary stones.

Study Details

The purpose of this study is to evaluate the safety and performance of the ELS to treat urinary stones. The ELS is intended to break urinary stones into small fragments that can pass during or after the procedure with less or no discomfort. Eligible patients are male or females, age 21 or older, with a single urinary stone in the ureter. Participants will undergo the ELS procedure and then be evaluated 30 days later for the presence or absence of urinary stone fragments on a CT scan. Subjects who still have stone present at Day 30 will be evaluated again at Day 60. Other outcome measures will be changes in pain, quality of life, and return to normal daily activities/work.

Key Dates

Start date
May 1, 2025
Status verified
Apr 2025
Primary completion
May 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
101 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: The ELS Trial is a prospective, multi-center, single arm study.
    All Subjects who qualify to participate in the ELS Trial will receive the experimental ELS procedure.

Primary Outcome Measure

Primary Outcome Measure [ Time Frame: From ELS treatment to 30 Days afterward. ]

Central Contacts

Locations (16)

FacilityCityStateZIPSite coordinators
Arizona State Urological Research InstitutePhoenixArizona85225
Clinical Research Coordinator
602-842-5305
Pratik Patel, MD (PRINCIPAL_INVESTIGATOR)
Michael G. Oefelein Clinical TrialsBakersfieldCalifornia93301
Evelyn De La Cruz, MD
661-310-1063
Michael Oefelein, MD (PRINCIPAL_INVESTIGATOR)
San Diego Clinical TrialsLa MesaCalifornia91942
Brian Hamblen
619-248-8517
Mohamed Bidair, MD (PRINCIPAL_INVESTIGATOR)
Golden State UrologySacramentoCalifornia95823
Clinical Research Coordinator
925-699-7545
Prithipal Sethi, MD (PRINCIPAL_INVESTIGATOR)
University of Miami HospitalMiamiFlorida33136
Elena Cortizas
305-243-3593
Hemendra Shah, MD (PRINCIPAL_INVESTIGATOR)
Georgia UrologyRoswellGeorgia300076
Clinical Research Coordinator
404-943-9654
Adam Mellis, MD (PRINCIPAL_INVESTIGATOR)
Comprehensive Urologic CareLake BarringtonIllinois60010
Sunny Clinical Research Coordinator
847-382-5080
Ning Wu, MD (PRINCIPAL_INVESTIGATOR)
Wichita Urology GroupWichitaKansas67226
Clinical Research Coordinator
316-636-6100
Timothy Richardson, MD (PRINCIPAL_INVESTIGATOR)
Minnesota UrologyWoodburyMinnesota55125
Emmanuel Ogbu
651-999-7032
Aaron Milbank, MD (PRINCIPAL_INVESTIGATOR)
University of Rochester Medical CenterRochesterNew York14620
Austin Jackson
585-602-0556
Rajat Jain, MD (PRINCIPAL_INVESTIGATOR)
SUNY - Upstate Medical UniversitySyracuseNew York13210
Diane Gould
315-464-6105
Scott Wiener, MD (PRINCIPAL_INVESTIGATOR)
DukeDurhamNorth Carolina27710
Brian Cuffe
919-681-5557
Robert Medairos, MD (PRINCIPAL_INVESTIGATOR)
Urology San AntonioSan AntonioTexas78229
Manuel Hernandez
210-617-4116
Matthias Hofer, MD (PRINCIPAL_INVESTIGATOR)
University of VirginiaCharlottesvilleVirginia22903
Alexandra Stauffer
434-924-6869
Wesley Pate, MD (PRINCIPAL_INVESTIGATOR)
University of Virginia Community HealthCulpeperVirginia22701
Alexandra Stauffer
434-924-6869
Gregg Eure, MD (PRINCIPAL_INVESTIGATOR)
Urology of VirginiaVirginia BeachVirginia23462
Julia Csenar
757-452-3463
James Young, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ